There is no evidence that less frequent financial reporting impairs company performance, market functioning, or the quality of investor information.

More than 60 million years on from its final day on Earth, there's a dinosaur we owe an apology. Paleontologists confirm that the Tyrannosaurus rex locked in combat with a Triceratops in the famous ...

We're in the midst of an evolution with immersive technology. Marketing efforts Meta's Oculus and Apple's Vision Pro emphasize consumer-centric applications such as gaming, but this consumer-centric ...

While research has long held the far right to be the most persistent domestic terror threat, a controversial new report ...

She’d overseen the emotionally exhausting closure of two company offices, one in Portland and another, smaller but cherished, in Charlotte, as part of a post-pandemic adjustment to remote work and ...

The “placebo-adjusted” weight loss achieved by Metsera’s drug at 28 weeks of treatment is roughly equal to the 13% achieved by Zebpound at the same stage in a Phase 3 study called Surmount-1, Risinger ...

Abstract: Overall Equipment Effectiveness (OEE) stands as a key performance metric widely adopted in the manufacturing industry, aiding in enhancing productivity. This metric offers a comprehensive ...

Reno, Nev., Oct. 13, 2025 (GLOBE NEWSWIRE) -- American Battery Technology Company (NASDAQ: ABAT), an integrated critical battery materials company commercializing both its primary battery mineral ...

RICHMOND, Va.—You might think the state that is the undisputed epicenter of global internet traffic has a leg up on managing the challenges of the artificial intelligence arms race. So far, it’s not ...

Heritage Petroleum Company used Cogent DataHub software to integrate new IoT-enabled well-monitoring devices. A reorganization in 2018 of Petrotrin, the state oil company of Trinidad and Tobago, ...

Eli Lilly and Company (NYSE:LLY) is among the 10 Best Money Making Stocks to Invest In. According to a U.S. registry of clinical trials, the firm has halted an experimental drug study designed to stop ...

On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. The company cited strategic ...